Balch C - Search Results

1

Tackling multidrug resistance mediated by efflux transporters in tumor-initiating cells.

McIntosh K, Balch C, Tiwari AK. McIntosh K, et al. Among authors: balch c. Expert Opin Drug Metab Toxicol. 2016 Jun;12(6):633-44. doi: 10.1080/17425255.2016.1179280. Epub 2016 May 4. Expert Opin Drug Metab Toxicol. 2016. PMID: 27116192 Review.

2

Pyrimido[1″,2″:1,5]pyrazolo[3,4-b]quinolines: Novel compounds that reverse ABCG2-mediated resistance in cancer cells.

Karthikeyan C, Malla R, Ashby CR Jr, Amawi H, Abbott KL, Moore J, Chen J, Balch C, Lee C, Flannery PC, Trivedi P, Faridi JS, Pondugula SR, Tiwari AK. Karthikeyan C, et al. Among authors: balch c. Cancer Lett. 2016 Jun 28;376(1):118-26. doi: 10.1016/j.canlet.2016.03.030. Epub 2016 Mar 21. Cancer Lett. 2016. PMID: 27012188

3

Natural Polyphenols in Cancer Chemoresistance.

Hussain SA, Sulaiman AA, Balch C, Chauhan H, Alhadidi QM, Tiwari AK. Hussain SA, et al. Among authors: balch c. Nutr Cancer. 2016 Aug-Sep;68(6):879-91. doi: 10.1080/01635581.2016.1192201. Epub 2016 Jul 1. Nutr Cancer. 2016. PMID: 27366999 Review.

4

The Epigenomics of Embryonic Pathway Signaling in Colorectal Cancer.

Balch C, Ramapuram JB, Tiwari AK. Balch C, et al. Front Pharmacol. 2017 May 19;8:267. doi: 10.3389/fphar.2017.00267. eCollection 2017. Front Pharmacol. 2017. PMID: 28579957 Free PMC article. Review.

5

Improving gastric cancer preclinical studies using diverse in vitro and in vivo model systems.

Chang HR, Park HS, Ahn YZ, Nam S, Jung HR, Park S, Lee SJ, Balch C, Powis G, Ku JL, Kim YH. Chang HR, et al. Among authors: balch c. BMC Cancer. 2016 Mar 9;16:200. doi: 10.1186/s12885-016-2232-2. BMC Cancer. 2016. PMID: 26955870 Free PMC article.

6

Growth inhibition of ovarian tumor-initiating cells by niclosamide.

Yo YT, Lin YW, Wang YC, Balch C, Huang RL, Chan MW, Sytwu HK, Chen CK, Chang CC, Nephew KP, Huang T, Yu MH, Lai HC. Yo YT, et al. Among authors: balch c. Mol Cancer Ther. 2012 Aug;11(8):1703-12. doi: 10.1158/1535-7163.MCT-12-0002. Epub 2012 May 10. Mol Cancer Ther. 2012. PMID: 22576131

7

A pathway-based approach for identifying biomarkers of tumor progression to trastuzumab-resistant breast cancer.

Nam S, Chang HR, Jung HR, Gim Y, Kim NY, Grailhe R, Seo HR, Park HS, Balch C, Lee J, Park I, Jung SY, Jeong KC, Powis G, Liang H, Lee ES, Ro J, Kim YH. Nam S, et al. Among authors: balch c. Cancer Lett. 2015 Jan 28;356(2 Pt B):880-90. doi: 10.1016/j.canlet.2014.10.038. Epub 2014 Nov 4. Cancer Lett. 2015. PMID: 25449779 Free article.

8

Systematic approach identifies RHOA as a potential biomarker therapeutic target for Asian gastric cancer.

Chang HR, Nam S, Lee J, Kim JH, Jung HR, Park HS, Park S, Ahn YZ, Huh I, Balch C, Ku JL, Powis G, Park T, Jeong JH, Kim YH. Chang HR, et al. Among authors: balch c. Oncotarget. 2016 Dec 6;7(49):81435-81451. doi: 10.18632/oncotarget.12963. Oncotarget. 2016. PMID: 27806312 Free PMC article.

9

The role of chromatin, microRNAs, and tumor stem cells in ovarian cancer.

Balch C, Nephew KP. Balch C, et al. Cancer Biomark. 2010-2011;8(4-5):203-21. doi: 10.3233/CBM-2011-0214. Cancer Biomark. 2010. PMID: 22045354

10

Epigenetic targeting therapies to overcome chemotherapy resistance.

Balch C, Nephew KP. Balch C, et al. Adv Exp Med Biol. 2013;754:285-311. doi: 10.1007/978-1-4419-9967-2_14. Adv Exp Med Biol. 2013. PMID: 22956507 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

513 results

Search Page